Edition:
United Kingdom

Alembic Pharmaceuticals Ltd (ALEM.NS)

ALEM.NS on National Stock Exchange of India

422.30INR
23 May 2018
Change (% chg)

Rs-15.25 (-3.49%)
Prev Close
Rs437.55
Open
Rs435.20
Day's High
Rs437.00
Day's Low
Rs418.50
Volume
35,018
Avg. Vol
81,591
52-wk High
Rs608.00
52-wk Low
Rs418.50

Latest Key Developments (Source: Significant Developments)

Alembic Pharmaceuticals March-Qtr Net Profit Rises
Wednesday, 16 May 2018 

May 16 (Reuters) - Alembic Pharmaceuticals Ltd ::RECOMMENDED FINAL DIVIDEND OF 4 RUPEES PER SHARE.MARCH QUARTER CONSOL NET PROFIT 937.9 MILLION RUPEES VERSUS PROFIT 930.4 MILLION RUPEES YEAR AGO.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 8.53 BILLION RUPEES VERSUS 7.41 BILLION RUPEES YEAR AGO.  Full Article

Alembic Pharmaceuticals' Panelav Unit Gets Zero 483 Observations From U.S. FDA
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Alembic Pharmaceuticals Ltd ::SUCCESSFUL U.S. FDA INSPECTION AT API FACILITY AT PANELAV.THERE WERE ZERO 483 OBSERVATIONS AT THE FACILITY.  Full Article

Alembic Pharmaceuticals Says U.S. FDA Grants Orphan-Drug Designation To Rhizen Pharmaceuticals
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Alembic Pharmaceuticals Ltd ::U.S. FDA GRANTS ORPHAN-DRUG DESIGNATION FOR TENALISIB TO RHIZEN PHARMACEUTICALS S.A. (RHIZEN).  Full Article

Alembic Pharma Gets U.S. FDA Nod For Generic Drug to Treat Overactive Bladder
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Alembic Pharmaceuticals Ltd ::GETS U.S. FDA NOD FOR DARIFENACIN EXTENDED-RELEASE TABLETS.DRUG IS INTENDED TO TREAT OVERACTIVE BLADDER.  Full Article

India's Alembic Pharma Sept-qtr consol PAT rises
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Alembic Pharmaceuticals Ltd ::Says U.S. formulations business continues to face price erosion on some key products; India branded business showing signs of recovery‍​‍​.Sept quarter consol PAT 1.22 billion rupees versus 1.20 billion rupees year ago.Sept quarter consol revenue from operations 7.89 billion rupees versus 8.79 billion rupees year ago.  Full Article

Alembic Pharma buys generic drug developer Orit Laboratories
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Alembic Pharmaceuticals Ltd ::Says ‍co buys U.S. based generic drug developer Orit Laboratories LLC​.  Full Article

Alembic Pharma's Panelav facility gets EIR from USFDA for March inspection
Wednesday, 5 Oct 2016 

Alembic Pharmaceuticals Ltd :Formulation facility located at Panelav has received EIR from US FDA for the inspection carried out by them in March, 2016..  Full Article

Alembic Pharma June-qtr consol profit rises
Friday, 29 Jul 2016 

Alembic Pharmaceuticals Ltd : June-quarter consol net profit 1.04 billion rupees versus 717.3 million rupees last year . June-quarter consol net sales 7.27 billion rupees versus 5.82 billion rupees last year .  Full Article

Alembic Pharmaceuticals gets USFDA tentative approval for Febuxostat tablets
Tuesday, 5 Jul 2016 

Alembic Pharmaceuticals Ltd : Alembic Pharmaceuticals receives USFDA tentative approval for Febuxostat tablets . Alembic has settled the case with Takeda and will launch its generic as per terms of settlement .  Full Article

Alembic Pharma says no USFDA observations for co's API facilities at Panelav
Thursday, 30 Jun 2016 

Alembic Pharmaceuticals Ltd : Co's api facilities api i and api II both located at panelav have been inspected by usfda between June 20 and June 29 . The company did not receive any form 483 observations. .  Full Article

BRIEF-Alembic Pharmaceuticals' Panelav Unit Gets Zero 483 Observations From U.S. FDA

* THERE WERE ZERO 483 OBSERVATIONS AT THE FACILITY Source text - https://bit.ly/2Hl7Sul Further company coverage: